20% Upper Circuit: Pharma Stock Soars After Robust Q4 Results and Debt Reduction

Synopsis: A Gujarat-based injectable pharmaceutical maker posts its strongest annual numbers yet, with profit nearly doubling and revenue surging over 40% in FY26.

Shares of an Ahmedabad-based pharmaceutical manufacturer locked into a 20% upper circuit on Tuesday after the company reported a sharp jump in both quarterly and full-year earnings for FY26, drawing renewed attention from retail investors tracking smallcap pharma names.

With a market cap of ₹ 1,304 Crore, the shares of Sakar Healthcare Ltd. are trading at a price of₹ 586.95 i.e. 10.82 percent up from its previous closing price of₹ 529.6. In Tuesday trading session it hit an upper circuit of 20% at ₹ 635.5 i.e. 20% above its previous closing price. It currently trades at P/E of46.72.

Strong Revenue Momentum Across the Year

Sakar Healthcare Limited reported consolidated revenue from operations of ₹251.74 crore for FY26, up from ₹177.58 crore in FY25 – a year-on-year rise of over 41%. Total income for the full year came in at ₹254.02 crore against ₹178.90 crore a year ago. For Q4 FY26 alone, revenue from operations stood at ₹71.10 crore, compared to ₹50.24 crore in Q4 FY25, reflecting continued momentum into the final quarter.

Profit Nearly Doubles on Operating Leverage

The company’s consolidated net profit for FY26 came in at ₹30.48 crore, up sharply from ₹17.50 crore in FY25 – a jump of roughly 74%. For Q4 FY26, net profit stood at ₹11.02 crore versus ₹5.76 crore in the year-ago quarter. Profit before tax for the full year was ₹39.76 crore compared to ₹21.53 crore in FY25. The improvement was aided by operating leverage, with total expenses growing at a slower pace than revenue. Finance costs declined from ₹8.54 crore in FY25 to ₹7.86 crore in FY26, reflecting the company’s ongoing debt reduction efforts.

Earnings Per Share Surges; Balance Sheet Strengthens

Basic earnings per share for FY26 stood at ₹13.70 against ₹7.97 in FY25, based on a face value of ₹10 per share. On the balance sheet, total assets grew to ₹481.09 crore as of 31 March 2026, from ₹415.35 crore a year earlier. Reserves excluding revaluation reserves rose to ₹302.29 crore from ₹260.73 crore, while total equity stood at ₹324.54 crore versus ₹285.56 crore in FY25.

Debt Reduction and Cash Flow Signal Financial Discipline

Beyond the profit numbers, Sakar Healthcare’s balance sheet showed clear signs of deleveraging. Non-current borrowings fell to ₹31.35 crore as of 31 March 2026, down from ₹53.59 crore a year earlier, even as the company continued investing in fixed assets. Capital expenditure on property, plant, and equipment stood at ₹28.35 crore during FY26. Net cash flow from operating activity rose to ₹49.26 crore from ₹34.03 crore in FY25, suggesting the company is generating sufficient internal accruals to fund both growth and debt repayment without straining liquidity.

About the Company

Sakar Healthcare Limited is an Ahmedabad-based pharmaceutical manufacturer focused on injectable and oral dosage forms. Its product portfolio includes liquid orals, cephalosporin tablets and capsules, dry powder syrups, dry powder injections, liquid injectables in ampoules and vials, and lyophilized injections. The company has a wholly owned subsidiary, Sakar Oncology Private Limited, which had no business transactions during FY26.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 20% Upper Circuit: Pharma Stock Soars After Robust Q4 Results and Debt Reduction appeared first on Trade Brains.